Skip to main content

Malignant Liver Tumors (Metastatic Liver Disease)

  • Chapter
  • First Online:
Clinical Algorithms in General Surgery

Abstract

Treatment for metastatic disease to the liver involves understanding the full disease burden, including the primary tumor, and disease behavior. Dedicated liver imaging is essential to determine the number and distribution of hepatic lesions. The potential functional liver remnant must be ascertained. Depending on previously mentioned factors, surgical resection or liver-directed therapies can offer enhanced survival but must be balanced with systemic therapy, which should always be considered in metastatic disease. Surgery for the primary tumor should be considered in addition to the liver but may occur either in a staged or combined setting. Surveillance should occur following treatment to monitor for disease recurrence. Patients with hepatic disease that progresses on first-line chemotherapy should be switched to second-line therapy and monitored. For those who have disease that is unresectable and progressive, systemic therapy or a clinical trial remain the only options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Covey AM, Brown KT, Jarnagin WR, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008;247:451–5.

    Article  Google Scholar 

  2. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. JCO. 2009;27(20):3379–84.

    Article  Google Scholar 

  3. NCCN Clinical Practice Guidelines in Oncology, Colon Cancer. Version 2.2017 – March 13, 2017. NCCN.org.

  4. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25.

    Article  Google Scholar 

  5. Van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. JCO. 2016;34:1723–31.

    Article  Google Scholar 

  6. Zacharias AJ, Jayakrishnan TT, Rajeev R, et al. Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis. PLoS One. 2015;10:e0139940.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mineyev, N.M., Chaffee, K.M., Wong, J. (2019). Malignant Liver Tumors (Metastatic Liver Disease). In: Docimo Jr., S., Pauli, E. (eds) Clinical Algorithms in General Surgery . Springer, Cham. https://doi.org/10.1007/978-3-319-98497-1_80

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98497-1_80

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98496-4

  • Online ISBN: 978-3-319-98497-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics